<DOC>
	<DOCNO>NCT01891669</DOCNO>
	<brief_summary>To assess safety tolerability increase dose level PF-06263507 patient advance solid tumor order determine maximum tolerate dose select recommend Phase 2 dose .</brief_summary>
	<brief_title>A Study Of PF-06263507 In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Diagnosis solid tumor advanced/metastatic resistant standard therapy standard therapy available . Performance Status 0 1 . Adequate bone marrow , kidney , liver , heart function . Brain metastases require steroid . Major surgery anticancer therapy within 4 week study treatment start . Active bacterial , fungal viral infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>ADC 5T4</keyword>
	<keyword>PF-06263507</keyword>
	<keyword>solid tumor</keyword>
	<keyword>lung cancer</keyword>
	<keyword>breast cancer</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>cancer</keyword>
	<keyword>tumor</keyword>
	<keyword>neoplasm metastasis</keyword>
</DOC>